Met-CCL5 antagonizes CCR1 and CCR5 activation and function in response to their natural ligands CCL3-5, and this blockade is able to reduce inflammation in models of induced inflammatory and autoimmune diseases, but also after MI [8]. Here, CCR5 is linked to autoimmune disease.